INmune Bio: INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms

This collaboration primarily aims to concentrate on expediting production of the recessive dystrophic epidermolysis bullosa (RDEB) therapy CORDStrom. An independent technology and innovation organisation, CGT Catapult focuses on The post INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms appeared first on Pharmaceutical Business review.